The spin-off is aimed at achieving better growth.
JBM Healthcare, a subsidiary of Jacobson Pharma, has applied for a listing on and permission to deal in its shares on the main board of The Stock Exchange of Hong Kong Limited (HKEX), the group said in a press release. The separate listing of JBM constitutes a proposed spin-off of JBM by the group under the listing rules.
The proposed spin-off is expected to enhance strategic focus and risk management whilst providing direct access to capital markets.
Jacobson Pharma chairman and CEO Derek Sum said this initiative “will act as a catalyst for resetting both our capabilities and cost base as well as delivering value-creation opportunities to both businesses.”
Do you know more about this story? Contact us anonymously through this link.